Showing 5541-5550 of 7686 results for "".
- Biosimilar News: FDA Approves Stelara Biosimilar Wezlanahttps://practicaldermatology.com/news/biosimilar-news-fda-approves-stelara-biosimilar-wezlana/2462118/The U.S. Food and Drug Administration (FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Stelara (ustekinumab) for psoriasis and multiple other inflammatory diseases. The FDA granted the approval of Wezlana to Amgen, Inc. Wezlana, like Stelar
- National Rosacea Society Awards 2023 Research Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-2023-research-grants/2462117/The National Rosacea Society (NRS) has announced that it will contribute funding for one new study, continue funding for two ongoing studies, as part of its grant program to advance rosacea research. "Ongoing research into the pathologic processes of rosacea has ena
- Ventyx Biosciences Halts Trial for Experimental Psoriasis Drughttps://practicaldermatology.com/news/ventyx-biosciences-halts-trial-for-experimental-psoriasis-drug/2462116/Ventyx Biosciences has announced it is halting development of an experimental psoriasis drug due to missed internal targets required for it to advance beyond Phase 2, according to the company. The drug, VTX958, had shown acceptable safety and efficacy, and had achevied with its 225 mg B
- Positive Clinical Data Show Potential of STP705 for Focal Fat Reductionhttps://practicaldermatology.com/news/sirnaomics-presents-positive-clinical-data-of-stp705-for-focal-fat-reduction/2462111/New data for the investigative STP705 injectible for focal fat reduction (FFR) are "encouraging," according to the manufacturer, who presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas. The safety an
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade.</
- Almirall Highlights World Psoriasis Day With the Nina Serieshttps://practicaldermatology.com/news/world-psoriasis-day/2462102/October 29, 2023 is World Psoriasis Day, and Almirall is highlighting the impact of this disease on the wellbeing of individuals, their families, and friends through the series Nina, and with the support of the International Federation of Psoriasis Associations. Nina
- Exploring the Sunscreen Paradoxhttps://practicaldermatology.com/news/exploring-the-sunscreen-paradox/2462101/Sunscreen use may provide people with a false sense of security. The so-called sunscreen paradox suggests that individuals with higher levels of sun exposure also tend to use more but not an adequate quantity of sunscreen or other sun-protection measures, providing a false sense of
- Biosimilar News: YUFLYMA Added to CarePartners Specialty Pharmacy Cost Savings Programshttps://practicaldermatology.com/news/biosimilar-news-yuflyma-added-to-carepartners-specialty-pharmacy-cost-savings-programs/2462100/Celltrion USA, Inc.’s US Food and Drug Administration-approved biosimilar, YUFLYMA (adalimumab-aaty) has been added to CarePartners Specialty Pharmacy Cost Savings Programs. YUFLYMA is a high-concentration (100mg/mL) and citrate-free formulation of the Humira (adal
- Study: Psoriasis Not Caused by Somatic Mutationshttps://practicaldermatology.com/news/study-psoriasis-not-caused-by-somatic-mutations/2462099/Psoriasis is not caused or spread by spontaneous genetic mutations in the skin, new research suggests. Researchers from the Wellcome Sanger Institute in Hinxton, U.K. and collaborators sequenced skin samples from 111 people with psoriasis. They didn’t find any mutated ge
- Nemolizumab Continues to Wow in PNhttps://practicaldermatology.com/news/nemolizumab-shows-continued-promise-in-pn/2462095/Nemolizumab monotherapy significantly and rapidly improves itch and skin lesions in patients with prurigo nodularis, with clinically meaningful improvements seen as early as week four, according to results from the OLYMPIA 2 Trial, which appears in the